Cardiovascular Disease Gets Easier To Predict With Globorisk, New Global Risk Model
Cardiovascular diseases (CVD), like heart attack and stroke, are one of the four main types of non-communicable diseases (NCDs). According to the World Health Organization (WHO), NCDs kill 38 million people each year — and Globorisk, a newly developed risk factor equation, might reduce these numbers.
Researchers responsible for the equation said tracking risk factors and “offering risk-based multidrug treatment and counseling are cost-effective interventions for reduction of NCDs.” In order to measure global progress, they need sets of data from different countries. And in order to get the right amount of information, researchers’ analyzed eight prospective cohort studies (more than 50,000 participants), including the Honolulu Heart Program, Multiple Risk Factor Intervention Trial, and Women’s Health Initiative Clinical Trial.
The equations — one for fatal CVD and another for fatal plus non-fatal CVD — factored in predictors, such as smoking, blood pressure, diabetes, cholesterol, as well as the effects age and sex had on CVD worldwide over a span of 10 years in 11 different countries. The results showed risk of fatal CVD was lowest in South Korea, Spain, Japan, and Denmark, while it was highest in the Czech Republic, China, Iran, and Mexico.
Additionally, in low risk countries, only five to 10 percent of men and women had more than a 10 percent risk for fatal CVD. But researchers found in China, 33 percent of men and 28 percent of women had a 10 percent risk or higher. Overall, CVD was worse for men and women in developing countries versus developed ones. Though that’s not to say develop countries are better off; a portion of the population in the United States, England, Japan, Denmark, and Spain face high risk of CVD.
"This new tool allows healthcare professionals around the world to make optimal clinical decisions about treatment of their patients and for health policy makers to efficiently allocate resources to CVD prevention," said Goodarz Danaei, assistant professor of global health at Harvard Chan School, said in a press release.